TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail tested for aggressive lymphomas
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in patients whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments. The main goal is to find the safest and most effective dose of the dru…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New drug combo tested to fight tough blood cancers
Disease control OngoingThis study is testing if adding a new drug called selinexor to the standard chemotherapy regimen (RCHOP) is safe and more effective for treating B-cell non-Hodgkin's lymphoma. It will first find the safest dose of the combination, then see how well it works for newly diagnosed pa…
Matched conditions: TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC